ROR1

Targeting ROR1 in Chronic Lymphocytic Leukemia: Insights from the Zilovertamab and Ibrutinib Combination in High-Risk del(17p) Disease

A phase 1b/2 study evaluating zilovertamab combined with ibrutinib in relapsed/refractory CLL reveals safety, mechanistic inhibition of ROR1 signaling pathways, and a potential efficacy signal in del(17p) patients warranting further studies